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Abstract
Whereas moderately increased cellular oxidative stress is supportive for cancerous growth of cells,
excessive levels of reactive oxygen species (ROS) is detrimental to their growth and survival. We
demonstrated that high ROS levels, via increased oxidized glutathione (GSSG), induce isoform-
specific S-glutathionylation of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3)
at the residue Cys206, which is located near the entrance to the 6-phosphofructo-2-kinase catalytic
pocket. Upon this ROS-dependent, reversible, covalent modification, a marked decrease in its
catalytic ability to synthesize the Fructose-2,6-bisphosphate (Fru-2,6-P2), the key glycolysis
allosteric activator, was observed. This event was coupled to a decrease in glycolytic flux and an
increase in glucose metabolic flux into the pentose phosphate pathway (PPP). This shift, in turn,
caused an increase in reduced glutathione (GSH) and, ultimately, resulted in ROS detoxification
inside HeLa cells. The ability of PFKFB3 to control the Fru-2,6-P2 levels in an ROS-dependent
manner allows the PFKFB3-expressing cancer cells to continue energy metabolism with a reduced
risk of excessive oxidative stress and, thereby, to support their cell survival and proliferation. This
study provides a new insight into the roles of PFKFB3 as switch that senses and controls redox
homeostasis in cancer in addition to its role in cancer glycolysis.
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Introduction
Oncogenic cell transformation involves switching to aberrant metabolic patterns and
mitochondrial impairment [1]. It has been well documented that cancer cells are prone to
autonomous metabolism that utilizes glycolysis and glutaminolysis as major catabolic
pathways for production of energy and anabolic precursors required for survival and rapid
growth [2]. As first theorized by Warburg, the majority of pyruvate from glycolysis is
converted to lactate [3]. However, a small but significant fraction of pyruvate still goes into
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the TCA cycle after conversion to acetyl-CoA as α-ketoglutarate produced from
glutaminolysis does [4]. Persistent running of the TCA cycle in impaired mitochondria
causes a fast buildup of reactive oxygen species (ROS) [5],[6]. Consequently, the levels of
ROS in cancer cells are higher than those of normal cells, despite the fact that normal cells
rely more heavily on oxidative phosphorylation than cancer cells do [7,8]. The ROS level
elevated such a way is known to support tumor progression [9]. Nonetheless, even in cancer
cells, ROS production must still be regulated below the detrimental level, so as not to face
the fatal effects associated with excessive oxidative stress [10].
One of the most abundant and regenerable cellular antioxidants employed for ROS
detoxification inside cells is glutathione (γ-glutamyl-cysteine-glycine), which exists in two
interchangeable redox states: reduced (GSH) and oxidized (glutathione disulfide: GSSG)
[11,12]. The ROS protection by glutathione is achieved by the formation of mixed disulfides
via a thiol exchange reaction (RS–SR + R′SH ↔ R′S–SR + RSH), in which a free electron is
donated to ROS [12]. Through this mechanism, GSH can detoxify heavy metals, organic
xenobiotics, and many other toxic metabolites which are produced as side products of
cellular metabolism [13]. As such, the concentration ratio of GSH to GSSG within cells
often serves as a sensitive indicator of oxidative stress [14]. In the presence of oxidative
stress, a thiol exchange reaction of GSH also can be made with proteins through a procedure
called S-glutathionylation, which describes the formation of a disulfide bridge between the
thiol group of glutathione and an accessible free thiol on proteins [15,16]. S-
glutathionylation is reversible and known to regulate signal transduction as well as
localization and functionality of redox-sensitive proteins [17,18].
The regeneration of GSH from GSSG is catalyzed by the enzyme glutathione reductase
(GR) at the expense of reduced nicotinamide adenine dinucleotide phosphate (NADPH).
Over 60% of NADPH is produced during the initial steps of the pentose phosphate pathway
(PPP) and the rest at the reactions following glutaminolysis [14]. The PPP diverges from
glycolysis, using glucose-6-phosphate as the entry substrate. The NADPH-producing
glucose-6-phosphate dehydrogenase (G6PDH) catalyzes the rate-limiting first step and the
turnover rate is determined by substrate concentration. Consequently, glucose metabolic flux
redirects to the PPP in situations where glycolysis is interrupted. The increased PPP flux
causes an increase in the NADPH production and the ROS detoxification, as well as the
increased production of precursors for anabolic metabolism [19]. This metabolic redirection
is especially important for cancer cells, which have to perform persistent glycolysis and
ROS regulation simultaneously [20–22]. Recent studies have suggested a possibility that
glycolysis, in cancer cells, is interrupted for ROS regulation via promotion of the PPP
through oxidative stress- and/or metabolic status-dependent mechanisms. Covalent
modifications of the glycolysis rate-regulating enzymes such as pyruvate kinase M (PKM)
and phosphofructokinase (PFK) have been suggested as the molecular models. Both S-
glutathionylation of PKM and O-linked glycosylation of PFK with N-acetyl glucosamine
caused decreases in glycolysis and increases in the PPP [23–25].
Among a family of bifunctional enzymes, PFKFB1–4, each of which controls glycolytic
flux by controlling the levels of the key glycolytic stimulator, fructose-2,6-bisphosphate
(Fru-2,6-P2) in a tissue-specific manner, PFKFB3 is cancer-predominant and responsible for
markedly increased glycolysis within cancer cells [26–29]. We observed that excessive ROS
induces S-glutathionylation of PFKFB3, causing a severe decrease in its 2-Kinase catalytic
activity for the synthesis of Fru-2,6-P2. The ROS-dependent modulation of PFKFB3 2-
Kinase activity resulted in a decrease in the Fru-2,6-P2 levels and an increase in the GSH/
GSSG ratios at the cellular level, implicating the redirection of glucose metabolic flux from
glycolysis to the PPP for regulation of the cellular oxidative stress homeostasis. The
experimental results are presented and discussed in this report.
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Isoform-specific S-glutathionylation of PFKFB3
To test whether or not PFKFB isoforms are regulated by oxidative stress, their capacity for
S-glutathionylation was tested using anti-glutathione antibody as probe. All four purified
recombinant PFKFB isoforms were treated with a physiological level (3 mM) of total
glutathione. But, the GSH to GSSG molar ratio was kept low at 1:1, which is extremely
favorable for S-glutathionylation, in order to detect the presence of S-glutathionylated
PFKFB isoforms, if any exist. The result of this test shows no other isoform, other than
PFKFB3, was S-glutathionylated in an immunoblot analysis, even if the ratio was raised to a
level 50-fold higher than physiological levels (Figure 1A). Moreover, S-glutathionylation of
human PFKFB3 was induced in a dose-dependent manner (Figure 1B) and a significant
extent of S-glutathionylation was also detected at a near physiological GSH to GSSG ratio
(30:1) (lane 3 in Figure 1B).
When tested for the functional effect of S-glutathionylation on PFKFB3, the 2-Kinase
activity for catalysis of Fru-2,6-P2 synthesis was also severely decreased in a dose-
dependent manner, implicating a correlation between the extent of S-glutathionylation and
the magnitude of activity loss (Figure 1C). Supporting the speculation that the observed
decreases in the enzymatic activity are caused by reversible S-glutathionylation, the full
enzyme activity was recovered upon treatment with reducing agents such as DTT or GSH.
Moreover, a ~20% loss of the catalytic activity of PFKFB3 for F-2,6-P2 synthesis was
observed at a near physiological ratio. This magnitude is comparable to or larger than losses
of the catalytic activities of pyruvate kinase M2 by S-glutathionylation or
phosphofructokinase by the attachment of O-linked N-acetyl glucosamine. A loss of the
catalytic activity of either enzyme in such a magnitude was observed to be significant
enough to divert glucose metabolic flux to the PPP [23,25].
The effect of S-glutathionylation on PFKFB3 structure/function relationships
To investigate the molecular basis of the functional effect of S-glutathionylation on
PFKFB3, we determined the crystal structure of glutathionylated PFKFB3 to 2.2 Å
resolution by a method of molecular replacement using the first PFKFB3 structure (PDB
code: 2AXN) as a search model [30]. The involved crystallographic data is summarized in
Table 1. The crystal structure revealed that this S-glutathionylation is made on Cys206
(Figure 2A, B, and C) and forms a hydrogen bond with Gln199. Among a total of nine
cysteine residues in PFKFB, Cys206 and Cys440 are unique to PFKFB3, whereas Cys102,
Cys155, Cys193, Cys252, Cys329, Cys388, and Cys426 are conserved among the isoforms.
Some residual electron densities were also shown on Cys440 but not sufficient to build in S-
glutathionylation with a certainty, when compared to those on Cys206 (Figure 2B).
However, this observation suggests an additional S-glutathionylation site in PFKFB3.
A sequence comparison between PFKFB isoforms was made and a part of the compared
sequences is shown in Figure 2D, in which C206 is unique to PFKFB3 and commonly exists
in both of the two known PFKFB3 splicing isomers, PFKFB3_1 and PFKFB3_2. In this
figure, two other conserved cysteine residues, Cys193 and Cys252, are also shown, because
they represent all other conserved cysteine residues, which are not subject to S-
glutathionylation according to Figure 1. Compared to Cys206, which is located on the
surface of the protein, Cys252 is buried deep inside and, thus, unable to contact with
glutathione (data not shown). Other cysteine residues belonging to this buried class are
Cys102, Cys155, Cys193, Cys252, Cys329, and Cys388. On the other hand, Cys193 and
Cys426 are on the surface but do not have a space wide enough to accommodate a bulky
group such as glutathione (data not shown). Our observation supports PFKFB3 isoform-
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specific S-glutathionylation as suggested by the immunoblots in Figure 1. This conclusion
was further supported by inter-species sequence comparisons. When the amino acid
sequences of the same PFKFB isoforms from other mammals including mouse, rat, and
primates were compared, the PFKFB3-unique Cys206 was found to be conserved between
all other mammals evaluated (data not shown).
S-glutathionylation at Cys206 did not induce any significant global conformational changes
in PFKFB3, when compared to that of the native protein (data not shown). The S-
glutathionylated cysteine residue is located within a loop, which is known to regulate the
entry of substrate, Fru-6-P, into the 2-Kinase catalytic pocket. The neighboring basic
residues, Arg131, His135, Arg208, and Lys205, are likely to attract the negatively charged
glutathione to the site and the negative charges from glutathione seems to facilitate
deprotonation of Cys206. Supporting this speculation, Lys205 and His135 are unique to
PFKFB3 (data not shown). The covalent attachment of a glutathione to the substrate entry
region is likely to doubly compromise the enzymatic activity as shown in Figure 2C. It is
likely that the addition of a bulky glutathione near the Fru-6-P binding pocket limits the
conformational flexibility of the loop, which is known to be necessary for Fru-6-P entry.
Additionally, the negatively charged glutathione is likely to exert repulsion on Fru-6-P,
which is also negatively charged. Compared to the dramatic changes seen in the 2-Kinase
activity, the phosphatase activity of PFKFB3, responsible for Fru-2,6-P2 hydrolysis,
remained essentially unchanged upon S-glutathionylation (data not shown), suggesting that
the structure/function effect is limited to the 2-Kinase.
To confirm the site of regulation, Cys206 was mutated to alanine (C206A) for tests.
Whereas the wild-type (WT) PFKFB3 is glutathionylated with a roughly 80% loss of kinase
activity at 1:1 molar ratios of GSH to GSSG (Figure 2E), C206A abrogated S-
glutathionylation with no loss of kinase activity under the same condition (Figure 2F).
Taken together, these findings suggest that Cys206 is crucial for S-glutathionylation-
dependent inactivation of PFKFB3 2-Kinase activity.
S-glutathionylation of PFKFB3 by cellular oxidative stress
To test whether S-glutathionylation of PFKFB3 is a cellular event, the effect of increased
oxidative stress on cellular PFKFB3 was investigated using cultured HeLa cells. To increase
cellular oxidative stress, we exogenously applied to the cells with hydrogen peroxide (H2O2)
or 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), both of which are routinely employed to
induce oxidative stress in cell studies. Whereas H2O2 increases cellular oxidative stress
through abnormal decomposition reactions, BCNU induces accumulation of cellular GSSG
by inhibiting glutathione reductase [31].
As shown in Figure 3A, both H2O2 and BCNU enhanced the generation of oxidative stress
in HeLa cells, when ROS production was analyzed employing chloromethyl-H2DCFDA
(CM-H2DCFDA, Invitrogen)-based fluorescence flow cytometry. A moderate increase in
ROS was observed after treating with relatively low concentrations of H2O2 or BCNU
(30μM and 10μM, respectively), whereas levels of ROS become excessively high with
higher concentrations (100μM and 80 μM, respectively).
Detection of cellular S-glutathionylated PFKFB3 was performed using a pull-down assay
followed by immunoblotting. The cells were preloaded with 1 mM cell-permeable
biotinylated GSH ethyl ester (Bio-GEE), which is widely accepted for this type of studies,
because it causes no significant changes in the cellular GSH concentrations or in the GSSG/
GSH ratios with uncompromised GSH redox reactivity [45,46]. The induction of high ROS
conditions was achieved by treating the cells with either H2O2 (100 μM) or BCNU (80μM).
S-glutathionylation of cellular PFKFB3 was induced by increased cellular oxidative stress
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regardless whether the protein is endogenous or exogenously overexpressed. S-
glutathionylation of both exogenously overexpressed PFKFB3 and endogenous PFKFB3
were detected in HeLa cells (Figure 3B,C, and D), whereas only overexpressed PFKFB3
was detected in 293T cells (Figure 3B), which has no endogenous PFKFB3. This pull down
assay confirmed that PFKFB3 is S-glutathionylated upon an increase in cellular oxidative
stress.
Consequences of PFKFB3 S-glutathionylation in an in-vitro model
S-glutathionylation of PFKFB3 greatly decreased its 2-Kinase activity, resulting in
decreases in the Fru-2,6-P2 levels. This event will lead to decreases in glycolytic flux,
because the rate-limiting step of glycolysis is catalyzed by phosphofructokinase (PFK)
whose activity is under the tight control by Fru-2,6-P2 levels [32,33]. Consequently, the
overall rate of glycolysis is controlled by Fru-2,6-P2 levels. However, unlike glycolysis, the
overall rate of glycolysis-interconnecting pentose phosphate pathway (PPP) is controlled by
abundance of the entry substrate, glucose-6-phosphate (Figure 4A). Because of this
fundamental difference in the rate-controlling mechanisms between the two pathways, it is
likely that the decreased glycolytic flux will reroute the metabolic flux to the PPP, resulting
in the increased PPP activity.
To test this possibility, an enzymatic assay for rerouting of carbohydrate metabolic flux
between glycolysis and PPP in response to S-glutathionylation-induced PFKFB3 kinase
inactivation was designed. In this assay, the competitive usage of Fru-6-P by PFKFB3 and
Glu-6-P dehydrogenase was assessed at varying doses of the GSH/GSSG ratio by measuring
Fru-2,6-P2 and NADPH (Figure 4B). The GSSG treatment of PFKFB3 decreased Fru-2,6-P2
levels and increased NADPH levels in a dose-dependent manner, implicating a decrease in
glycolysis and an increase in the PPP, respectively (Figure 4B). Thus, the results from this
experiment suggest that the S-glutathionylation of PFKFB3 is likely to reroute the glucose
metabolic flux from glycolysis to the PPP inside cells.
Cellular metabolic effects of PFKFB3 S-glutathionylation
With cultured HeLa cells, we tested the cellular validity of our model. In this experiment,
overexpression of WT-PFKFB3 and C206A was employed, to control the PFKFB3
abundance and the glycolytic rate. It was expected that the overexpression of both WT and
C206A would increase overall glycolytic flux with similar magnitudes. However, when the
oxidative stress is increased, WT, but not C206A, is S-glutathionylated, resulting in a sharp
decrease in the Fru-2,6-P2 production. As a consequence, a bottleneck in the glycolytic
pathway is created at the step for conversion of Fru-6-P to Fru-1,6-P2 and the upstream
substrates including Fru-6-P are rerouted into the PPP, producing greatly increased NADPH.
The magnitude of this redirecting must be dependent on the abundance of PFKFB3 whose
activity can be modulated in a ROS-dependent manner.
It was confirmed that the glycolytic rates indicated by the secreted lactate levels coincide
with the Fru-2,6-P2 levels in all test conditions (Figure 5A and B). Compared to the empty
vector, overexpression of WT-PFKFB3 increased the concentrations of Fru-2,6-P2 and the
release of lactate, however H2O2 (or BCNU)-induced oxidative stress abolished such
responses. On the other hand, overexpression of C206A displayed a consistent increase in
lactate and Fru-2,6-P2 levels both in the presence and absence of H2O2 or BCNU, compared
with empty vector control and WT-PFKFB3. Thus, acute oxidative stress triggers a ROS-
dependent S-glutathionylation of PFKFB3, resulting in decreased Fru-2,6-P2 levels and,
subsequently, glycolysis.
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We then tested whether the decreased rates of glycolysis caused by PFKFB3 S-
glutathionylation would coincide with increases in the PPP rates inside cells. When no
treatment was made, a slight decrease in Ribul-5P+Xyl-5P levels and NADPH levels
accompanied with an increase in the GSSG-to-GSH ratio in cells expressing WT and C206A
(Figure 5C, D, and E, respectively). This difference might be caused by increases in
glycolysis as a result of overexpressed PFKFB3. Treatment with oxidizing agents increased
intracellular NADPH concentrations in cells expressing WT, but not in cells expressing
C206A (Figure 5D). As expected, H2O2 or BCNU treatment moderately enhanced the
GSSG-to-GSH ratio in cells expressing WT, while the treatment excessively increased
GSSG levels in cells expressing C206A (Figure 5E). All together it was indicated that the
PFKFB3 S-glutathionylation plays an important role in the PPP activation and that the
magnitude of activation is significant enough to generate reducing equivalents under
oxidative conditions.
Regulation of cellular oxidative stress by PFKFB3 S-glutathionylation
Finally, we investigated if the increased PPP, as a result of PFKFB3 S-glutathionylation,
plays a significant role in controlling of cellular levels of ROS. When the cells were treated
with increasing doses of H2O2, control cells with an empty vector showed consistent
increases in ROS levels. However, cells expressing WT demonstrated ROS regulation
through which ROS levels decrease after an initial burst, which was shown at lower doses of
H2O2 (Figure 6A). This initial burst seems to be attributable to glycolysis stimulated by
increases in PFKFB3 abundance and in the resulting Fru-2,6-P2 levels. Altogether, these
results strongly suggest that PFKFB3 plays a role in maintaining the levels of ROS below
the threshold toxic yet elevated enough to promote proliferation, oncogenic mutations, and
stress responses [21, 34].
To test whether this mechanism is relevant to cancer cell survival under oxidative stress, a
cell viability assay was performed. In response to ROS-inducing treatments by H2O2 or
BCNU, increased cell survival was observed from WT-PFKFB3 overexpression whereas an
insignificant difference was shown between C206A and the empty vector (Figure 6B and C).
The magnitude of the increase in cell survival rates was greater, when the treating
concentrations of H2O2 or BCNU were higher. This observation supports the argument that
the magnitude of the PPP influx is dependent on the magnitude of glycolytic flux. The
increased glycolytic flux by WT-PFKFB3 overexpression is represented as increased PPP
products, decreased ROS levels, and/or increased cell survival, after rerouting by S-
glutathionylation-dependent impairment of glycolysis. The overexpressed C206A is
incapable of S-glutathionylation-dependent rerouting and, as a consequence, its effects on
the PPP and ROS-neutralization are not dissimilar from those of the empty vector. In
conjunction with the previous sections, these results together suggest that the S-
glutathionylation of PFKFB3 in cancer cells promotes cellular resistance against ROS-
associated cell death. The results also reveal how efficiently glucose metabolism and cellular
ROS levels can be regulated by the S-glutathionylation of PFKFB3 in order to protect
cancer cells from oxidative stress. Hence, PFKFB3 can alternatively stimulate glycolysis
and the PPP, depending on the cellular oxidative stress levels.
Discussion
Aberrant metabolism and impairment of mitochondria are the hallmarks of cancer [35]. The
cancer-specific aberrant metabolism is represented by anomalously stimulated
glutaminolysis and glycolysis [2]. Persistent tumorigenic glycolysis and glutaminolysis
followed by the TCA cycle in impaired mitochondria produces ROS above the norm [5].
The excess ROS causes detrimental effects on cell growth and survival, unless counteracted
by a neutralization mechanism [6],[10]. The most ubiquitous biological reductant for
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detoxifying ROS inside cells is GSH, the reducing power of which is recovered by an
NADPH-dependent glutathione reductase. Over 60% of cellular NADPH is produced by the
PPP in mammals and, thus, the PPP has to be regularly stimulated in order to protect cells
from ROS [36,37]. Because glycolysis and the PPP are interconnected and because the PPP
rate is dependent on the availability of the entry substrate, modulation of glycolysis is
accompanied by an increase in the PPP. A possibility has been suggested that the
intermittent impairment of glycolysis may serve as a means for the regulation of oxidative
stress in cancer cells. In this regard, the recent reports on the regulation of the two
glycolysis-rate-limiting enzymes by posttranslational modifications suggest a molecular
physiological model for the regulation of oxidative stress homeostasis in proliferating cells.
It has been shown that ROS-dependent S-glutathionylation of pyruvate kinase M2 isoform
(PKM2) results in inhibition of glycolysis and promotes the PPP [38]. Similarly, the O-
linked glycosylation of phosphofructokinase (PFK) with N-acetyl glucosamine also inhibits
glycolysis and promotes the PPP [39]. Although two different covalent modifications were
suggested, both the studies revealed that the promoted PPP plays a crucial role in the
regulation of the cellular ROS levels for cell survival and proliferation.
We hypothesized that PFKFB3, which is known as the cancer-specific glycolysis pacemaker
protein, is also involved in ROS regulation in cancer cells. It has been speculated that
inactivation of PFKFB3 decreases glycolysis via decreased Fru-2,6-P2 and may increase the
PPP influx, resulting in regulation of ROS. To test this hypothesis, we investigated if the
catalytic activity of PFKFB3 for Fru-2,6-P2 synthesis is modulated by increased cellular
oxidative stress, if the modulated PFKFB3 activity induces an increase in the PPP via a
decrease in glycolysis, if the increased PPP reduces cellular oxidative stress, and if the
resulting reduction of cellular oxidative stress is significant enough to enhance viability of
cancer cells.
A set of Western blots and subsequent enzymatic experiments revealed that PFKFB3
activity and, hence, its influence on glycolysis is modulated by isoform-specific S-
glutathionylation. The isoform specificity of this oxidative stress-dependent covalent
modification seems to be valid across all mammals according to sequence analysis. An X-
ray crystallographic study revealed the site of S-glutathionylation and the associated
mechanism of activity modulation. An in vitro assay experiment designed to investigate the
interplay between glycolysis and the PPP showed increases in the PPP flux in response to S-
glutathionylation-induced PFKFB3 inactivation. Moreover, the results suggested that Fru-6-
P can be retrogradely routed to the PPP after conversion to G-6-P, when the glycolytic
consumption of Fru-6-P by PFK is limited. The results provided a biochemical foundation
that glucose metabolism can be alternatively routed between glycolysis and the PPP,
depending on the rate of either pathway.
The validity of our model was tested at the cellular level with the cultured HeLa cells. When
cellular oxidative stress was elevated by treating with H2O2 and BCNU, S-glutathionylation
of both the endogenous and overexpressed PFKFB3 was detected, using a widely accepted
affinity precipitation and immune blotting method. We showed that the cellular PFKFB3
activity regulates Fru-2,6-P2 levels and, thereby, glycolysis rates. Compared to the empty
vector, the WT-PFKFB3 overexpression increased levels of both Fru-2,6-P2 and secreted
lactate to a similar extent, implying an increase in overall glycolytic flux. Modulation of
PFKFB3 activity by elevated ROS decreases glycolysis and increases the PPP via rerouting
glycolytic metabolites. The magnitude of the rerouted flux must be dependent on the
magnitude of the initial glycolytic flux. Consequently, the PPP increase by WT-PFKFB3
overexpression is more efficient than that by the empty vector. But, such an increased
metabolic shift could not be elicited by C206A, although the mutant increased glycolysis to
the same extent as WT-PFKFB3. This is because the mutant is insensitive to ROS-
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dependent activity modulation and, thus, might be unable to elicit ROS-dependent regulation
of glycolysis and metabolic rerouting.
Subsequently, we investigated if the metabolic rerouting is related to changes in the
abundance of cellular GSH. Metabolic parameters and the GSSG/GSH ratios of the cells
treated with 4 mM cell-permeable GSH, ethyl ester GSH (GSHee), were not significantly
different from those of the untreated cells after 30 hrs of incubation. This result suggests that
the regulation of cellular oxidative stress homeostasis is to control the steady GSH/GSSG
ratios rather than the abundance of glutathione. Lastly, it was revealed that increases in the
PPP by PFKFB3 S-glutathionylation significantly reduce ROS levels and, thereby, enhance
cell viability. And, that ROS neutralization is more efficient, when the glycolytic flux was
stronger, as suggested by comparison of the WT-PFKFB3 overexpression and the empty
vector.
These results altogether provide a new understanding of how the S-glutathionylation of
PFKFB3 controls glucose metabolism, thereby regulating ROS levels in order to protect
cancer cells against oxidative stress. The PFKFB3 S-glutathionylation plays an additional
role for ROS regulation in cancer cells, which was originally suggested by PKM S-
glutathionylation. Modulation of the PFKFB3 activity regulates the glycolysis rate by
controlling the first glycolysis-committed step, conversion of Fru-6-P to Fru-1,6-P2, whereas
modulation of PKM plays a similar function by controlling the last step, conversion of
phosphoenol pyruvate to pyruvate. A question raised from this study is why the two opposite
ends of glycolysis are both involved in fulfillment of the same physiological goal, ROS
regulation.
Our speculation is that a decrease in glycolysis has an additional function to ROS regulation,
as if an increase in the PPP is more than just for NADPH production. In cancer cells which
are prone to autonomous metabolism, intermittent activation of the PPP is necessary for
biosynthesis of nucleotides, amino acids, and lipids for rapid cell proliferation. For the same
reasons, glycolysis also has to be periodically regulated such that cells can perform
biosynthesis of amino acids and phospholipids using the glycolysis intermediate metabolites
as precursors. Modulation of both PFKFB3 and PKM enables cells to secure large quantities
of the glycolysis intermediate metabolites necessary for many anabolic processes.
Otherwise, a harmonious biosynthesis using the PPP products would not be possible. In this
regard, the functional involvement of PFKFB3 S-glutathionylation in ROS regulation would
also suggest a possible role for PFKFB3 in cell cycle progression in cancer cells and a
broader and more general role for ROS in the regulation of numerous biological processes,
although further studies are necessary to elucidate the details of this mechanism. This new
understanding will contribute to the development of appropriate therapeutic strategies for
cancer prevention and treatment based on their redox profile.
Materials and Methods
Materials
The following materials were obtained from the sources indicated. Dimethyl sulfoxide
(DMSO), oxidized L-glutathione (GSSG), reduced L-glutathione (GSH), 1,3-bis(2-
chloroethyl)-1-nitrosourea (BCNU) (Sigma Chemical Co., St. Louis, MO, USA); Qdot 605
ITK streptavidin conjugate kit 2 μM solution, dextran alexafluor 488, anti-V5 antibody,
calceinacetoxymethyl ester, PLUS Reagent, lipofectamine LTX Reagent, biotinylated
glutathione ethyl ester (BioGEE) (Invitrogen Corporation, Carlsbad, CA, USA); anti-
glutathione monoclonal antibody (ViroGen Corporation); V5 antibody affinity purified
agarose immobilized conjugate (Bethyl Laboratories); goat anti-mouse glutaredoxin-1/
GLRX1 antibody (R&D Systems Inc.); glutaredoxin-1, glutaredoxin-1 antibody (Abcam).
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Plasmid Constructs and Mutagenesis
Full-length cDNA constructs for human PFKFB3 mutants, C206A, were generated by site-
directed mutagenesis using the QuikChange II XL Site-Directed Mutagenesis Kit
(Stratagene) and the commercially available vector pcDNA3.1/myc-HisA with human
PFKFB3 as template, following the manufacturer’s recommendations. Briefly, the mutant
strand synthesis reaction was carried out by an initial denaturation at 95°C for 1 min,
followed by 18 thermal cycles at 95°C for 50 s, 60°C for 50 s, and 68°C for 9 min 24 s, with
a final extension at 68°C for 7 min. To create the bacterial expression plasmids, C206A-
PFKFB3 was then subcloned from pcDNA3.1/myc-HisA into the pET3a vector using NheI
and BamHI restriction sites. All constructs were sequenced for verification.
Preparation and S-Glutathionylation of PFKFB isoforms and Western Blotting
The 6XHis-tagged human PFKFB1-4 wild-type isoforms and the PFKFB3 C206A mutant
were expressed in Escherichia coli BL21(DE3) pLysS and purified using Ni-NTA affinity
columns and, subsequently, Mono Q anion-exchange chromatography. The experimental
details are described elsewhere [40].
To induce protein S-glutathionylation, purified PFKFB isoforms (0.3 mg/ml) in 20 mM
Tris•HCl (pH 8.0), 10 mM NaPi, 5% glycerol, and 0.2 mM EDTA were incubated for 25
min with 3 mM glutathione (with the GSH/GSSG molar ratios of 1:1) in 50 mM Tris•HCl
pH 7.4 at room temperature. The samples were then mixed without reducing agent or
heating with Laemmli sample buffer containing 1 mM NEM for the alkylation of accessible
thiols on PFKFB3. Samples were then resolved in non-reducing SDS-PAGE, and
subsequently transferred to nitrocellulose membranes. The Membranes were then probed
with anti-glutathione antibody (Virogen), followed by detection with horseradish
peroxidase-conjugated secondary antibody (Novagen). Bands were visualized by enhanced
chemiluminescence (SuperSignal west pico, Pierce) according to the manufacturer’s
instructions. Membranes were subsequently re-probed with anti-PFKFB3 antibody
(Abgent).
Measurement of 2-Kase/2-Pase activity of PFKFB3
The catalytic activity of PFKFB3 2-Kinase for Fru-2,6-P2 synthesis was performed as
described previously[41]. The 2-Kinase reactions were performed first and the Fru-2,6-BP
produced was measured by a conventional enzyme coupled assay. The reaction mixture
contained 20 mM Tris•HCl (pH 8.5), 0.5 mM MgCl2, 0.1 mM ATP, and 10–20 μg PFKFB3.
The reaction was initiated by adding 0.05 mM Fru-6-P and incubating at 25 °C for 10 min,
and the concentration of Fru-2,6-P2 was determined every 5 min. Fru-2,6-P2 was measured
spectrophotometrically at 340 nm using the potato pyrophosphate-dependent 6-
phosphofructokinase (PPi-PF1K) activation assay.
To measure the catalytic activity of PFKFB3 2-Phosphatase for Fru-2,6-P2 hydrolysis, a
spectrophotometeric coupled enzyme assay was carried out using phosphoglucose isomerase
and Glu-6-P dehydrogenase as described previously. The reaction mixture (total volume
200μl) contained 100 mM Tris•HCl, pH 7.5, 0.2 mM EDTA, 100 μM NADP, 0.4 unit of
Glu-6-P dehydrogenase, and 1 unit of phosphoglucose isomerase. PFKFB3 (0.2–0.4 mg)
was used in the 2-Phosphatase activity assay. The reaction was initiated by the addition of
100 μM Fru-2,6-P2 and all experiment were run at 25 °C. NADPH formation was measured
at 340 nm using a microplate reader (Model 3550-UV, Bio- Rad).
S-Glutathionylation of PFKFB3 Crystals and Diffraction Data
The purified PFKFB3 was kept, after concentrating to 8 mg/ml protein, in 20 mM Tris•HCl
(pH 8.0), 10 mM NaPi, 5 mM β-mercaptoethanol, 5% glycerol. Crystals were prepared by
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the sitting-drop vapor-diffusion method with a 1:1 (v/v) mixture of the protein sample with a
reservoir solution of 50 mM MES pH 7 and 7% (w/v) polyethylene glycol 4000 [40].
Crystals with a size of 0.2 mm × 0.1 mm × 0.2 mm grew in two to three weeks.
Crystals were soaked with a cryoprotectant solution containing different molar ratios of
GSH/GSSG at constant total glutathione concentration of 5 mM. A soaked crystal was flash-
cooled at 100 K using an Oxford cryo-device and kept at the same temperature during data
collections. The diffraction data were collected at The Northeastern Collaborative Access
Team (NE-CAT) Beamline at the Advanced Photon Source, Argonne National Laboratory,
Argonne, IL. The X-ray source wavelength was 0.9792 Å. The data recorded on a ADSC
Q315 detector were integrated, merged, and scaled using XDS [42]. Statistics of the
diffraction data and structure refinement are summarized in Table 1. The crystals belong to
P6522 space group with the cell dimensions similar to those of the native protein. The
reduced data was formatted for the program suites of CCP4 [43] and 10% of the data was
marked for free R-factor measurements in subsequent structure refinements.
Structure Determination and Refinement
The search model was built from the coordinates of the PFKFB3•ADP•EDTA complex
structure (PDB accession code 2AXN) [30] by stripping all included ligand and solvent
molecules. The initial model was determined using REFMAC within the CCP4 suit and
processed through iterated cycles of manual model rebuilding and validation using the
program COOT [43].
Bindings of ligands were confirmed, referring to the |Fo|–|Fc| omit maps that were
generated, when Rcrys/Rfree reached 0.23/0.29 or below. Referring to these maps, GSH was
incorporated into the corresponding complex models. As summarized in Supplementary
Table 1, the final model of the glutathionylated PFKFB3 has Rcrys/Rfree of 0.209/0.257
using a total of 3,939 scatterers, including solvent molecules, against all available 37,905
reflections in the resolution range of 47.7–2.2 Å. The structure contains a total of 443 amino
acid residues of the 520 residue full-length protein. As in the PFKFB3•ADP•EDTA
complex, the C-terminus (residues 461–520) is mostly disordered. The pdb file of the
refined structure with the structure factor was deposited with an accession code 4MA4.
In Vitro Metabolic Rerouting between Glycolysis and the PPP
To measure in vitro metabolic rerouting between glycolysis and the PPP upon PFKFB3 S-
glutathionylation, a spectrophotometeric coupled enzyme assay was carried out using
PFKFB3, phosphoglucose isomerase, and Glu-6-P dehydrogenase. The combined reactions
of the first step of the PPP via phosphoglucose isomerase and Fru-2,6-P2 synthesis by
PFKFB3 were initiated by addition of 0.2 mM Fru-6-P. Formation of Fru-2,6-P2 and
NADPH were measured subsequently as representative products. The reaction mixture
contained 50 mM glycylglycine (pH 7.5), 0.5 mM MgCl2, 0.2 mM ATP, 0.4 mM β-
nicotinamide adenine dinucleotide phosphate (NADP), 0.2–0.6 unit of Glu-6-P
dehydrogenase, 1 unit of phosphoglucose isomerase, and 8–20 μg PFKFB3. The reaction
was initiated by adding 0.2 mM Fru-6-P and incubating at 25 °C for 10 min and collecting
aliquots at every 5 minutes. The aliquots were transferred into 125 mM NaOH. The NADPH
formation was directly measured at 340 nm and Fru-2,6-P2 produced was measured as
described above.
Cell Culture, Transient Transfection, and Oxidant Treatments
293T and HeLa cells were obtained from ATCC and cultured in DMEM containing 2 mM
glutamine, 10% fetal calf serum (FCS), 100 U/ml penicillin and 100 μg/ml streptomycin (all
from GIBCO-BRL). All cells were cultured in a humidified incubator at 37°C, 5% CO2.
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Cells expressing PFKFB3 and its mutant were established by transfecting cells with
pcDNA3.1/myc-HisA-PFKFB3 WT and mutant(s) using GeneJuice® transfection reagent
(Novagen). Overexpression of PFKFB3 was confirmed by immunoblotting analysis. BCNU
[N,N′-bis(2-chloroethyl)-N-nitro-sourea] and H2O2 (hydrogen peroxide) were from Sigma
and used as described in the text.
Detection of Glutathionylation of PFKFB3 in 293T and HeLa cells
293T and HeLa cells expressing PFKFB3 were loaded with 1 mM biotinylated glutathione
ethyl ester (BioGEE, Invitrogen) and incubated for 1 hr followed by an H2O2 treatment for
15 min or BCNU treatment for 3 hrs. The cells were lysed in a modified RIPA buffer (0.01
M sodium phosphate pH 7.2), 150 mM NaCl, 0.1mM EDTA, 1% Nonidet P-40, 1% sodium
deoxycholate, and 0.1% SDS, 10 mM N-ethylmaleimide) supplemented with a protease
inhibitor mixture (Roche). Glutathionylated PFKFB3 levels were measured after pull down
with streptavidin-dynabeads (Invitrogen) according to the manufacturer’s protocol followed
by reducing SDS-PAGE and Western blot analysis with anti-PFKFB3 antibody. For
detection of endogenous PFKFB3 glutathionylation, cells were treated with 10 μM
proteasome inhibitor MG132 for 8 hrs before BioGEE incubation. Then cells were prepared
as described above.
Determination of Cellular Metabolites
HeLa cells were plated at a density of 1×107 in T 175 culture flasks in DMEM containing
10% FCS, 2 mM glutamine, 100 U/ml penicillin and 100 μg/ml streptomycin. Cells
expressing a specific PFKFB3 mutant were established by transient transfection the
following day. After 36 hours of incubation, the media were replaced with fresh DMEM
containing either H2O2, BCNU, or GSHee at the indicated concentrations and time. Media
samples were collected for measuring the lactate secretion levels using a lactate oxidase-
based assay kit (Sigma-Aldrich). Cell extracts were prepared with the lysis buffer containing
0.01 M sodium phosphate (pH 7.5), 150 mM NaCl, 5 mM EDTA, 1% Nonidet P-40, and 5%
5-sulfosalicylic acid (SSA). Before each assay, ice cold 2M KOH was added to the SSA-
preserved sample for neutralization. The Fru-2,6-P2 level was determined in the collected
cells after the treatment by the method described previously [41].
For the quantification of the PPP, levels of ribulose 5-phosphate (Ribul-5P) and xylulose-5-
phosphate (Xyl-5P) were monitored. For this, the mixture of Ribul-5P, Xyl-5P, and
glyceraldehyde-3-phosphate (G-3P) was quantitated first and the quantity of G-3P was
subtracted. First, the quantification of mixture of the three was performed in a system
containing 58 mM glycylglycine, 3.3 mM Xyl-5P, 0.002% (w/v) cocarboxylase, 15 mM
magnesium chloride, 0.14 mM β-nicotinamide adenine dinucleotide, reduced form, 15 mM
MgCl2, 20 units a-glycerophosphate dehydrogenase, 5 units triosephosphate isomerase, 0.1
unit ribulose 5-phosphate 3-epimerase, and 5 units transketolase as described
previously[44]. Then, levels of G-3P have been measured under same condition but in the
absence of ribulose 5-phosphate 3-epimerase and transketolase. Protein concentration was
measured using QuantiPro BCA assay kit (Sigma-Aldrich) and metabolite concentrations
were normalized to the total cellular protein concentration.
NADP/NADPH, GSH/GSSG and ROS measurements
Cells were prepared as described above in Metabolite determination. The cellular GSH/
GSSG ratios and NADP/NADPH ratios were analyzed spectrophotometrically by using a
GSH/GSSG measurement kit or NADPH assay kit (Abcam) according to the manufacturer’s
instructions.
Seo and Lee Page 11













For ROS measurements, the medium was aspirated, pre-treated cells were washed 1x with
PBS, harvested by trypsinization, and processed for flow cytometry. Cells were
subsequently incubated with HBSS containing 10 μM chloromethyl-H2DCFDA (CM-
H2DCFDA, Invitrogen) in DMSO for 30 min at 37°C, while still maintaining the H2O2 or
BCNU treatment. The fluorescence of samples were analyzed by flow cytometry
(FACSCalibur®, Becton Dickinson Immunocytometry), using the CellQuest (BD
Bioscience) software.
Cell Viability assay
Cell viability assays were performed by trypan blue staining. Cells were plated at a density
of 3.5×104 per well in a 24-well plate in DMEM containing 10% FCS. Cells expressing the
PFKFB3 mutant were established by transient transfection the following day. After 20 hours
of incubation, the media were replaced with fresh DMEM containing H2O2, BCNU, or
GSHee at the indicated concentrations. After 30 hours of incubation with the vehicle or
compounds, cells were trypsinized and cell viability was determined by the trypan blue
exclusion assay using a hemacytometer.
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• A cancer-specific mechanism for ROS neutralization is necessary.
• PFKFB3 activity is down-regulated by ROS-dependent S-glutathionylation.
• S-glutathionylated PFKFB3 redirects metabolic flux to pentose phosphate
pathway.
• S-glutathionylation of PFKFB3 is involved in ROS neutralization in cancer.
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Figure 1. Isoform-specific S-glutathionylation of PFKFB3 and its functional effect
(a) Immunoblotting of S-glutathionylation of PFKFB isoforms after 25 min incubation with
3 mM 1:1 molar ratio of GSH to GSSG, using anti-glutathione antibody. SDS-PAGE
separated input PFKFB isoforms (1–4) were visualized by Coomassie blue staining as the
loading control. (b) Immunoblotting of a dose-dependent PFKFB3 S-glutathionylation after
25 min treatment with varying molar ratios of GSH to GSSG. Bottom: Immunoblotting of
input PFKFB3 using anti-PFKFB3 antibody. (c) 6-phosphofructo-2-kinase activity (2-
Kinase) of S-glutathionylated PFKFB3 after 25 min pre-treatment with varied molar ratio of
GSH to GSSG. The percentage activities against the control (without preincubation) are
represented (n=3 experiments).
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Figure 2. Position of S-glutathionylation in PFKFB3
(a) A ribbon diagram of the PFKFB3 dimer showing site of S-glutathionylation. S-
glutathionylation is shown in only one subunit for a clearer view. The two catalytic domains
are shown in different colors: the 2-Kinase domains, gray and magenta; the 2-Phosphatase
domains, light green and dark green. S-glutathionylated C206 is labeled as GS-C206 and the
position of Fru-6-P in the 2-Kinase catalytic pocket is also shown. (b) The glutathione
moiety (labeled as GS-) bound to C206 is shown with an |Fo|–|Fc| omit map at a 2.5σ level.
(c) Glutathione (GS-) bound to Cys206 is located on the kinase surface surrounded by basic
residues, Arg131, His135, and Lys205. Glutathione has a hydrogen bond with Gln199. The
protein residues are shown in yellow, glutathione in green, and the Fru-6-P and ADP in
magenta for comparison. (d) Amino acid sequence alignment among human PFKFB
isoforms, PFKFB1, PFKFB2, Two splicing variants of PFKFB3, and PFKFB4 from the
ClustalW program. Fully conserved, conserved, and similar residues at each position are
symbolized by an asterisk (*), colon (:), and dot (.), respectively. The conserved cysteine
residues are in bold type and yellow shading shows PFKFB3 isoform-specific S-
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glutathionylated cysteine residue. (e) Immunoblotting of WT-PFKFB3 and the C206A
mutant after pre-treatment with 3 mM 1:1 molar ratio of GSH to GSSG. (f) The 2-Kinase
activities of WT-PFKFB3 and the C206A mutant after 25 min pre-treatment with varied
molar ratio of GSH to GSSG.
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Figure 3. PFKFB3 S-glutathionylation induced by oxidative stress inside cancer cells
(a) ROS levels in HeLa cells after treatment with the varying amounts of H2O2 and BCNU.
Error bars denote SEM. (b) Detection of ROS-induced S-glutathionylation of cellular
PFKFB3. PFKFB3-overexpressing HeLa cells and 293T cells were treated with or without
1.5mM Bio-GEE and 100 μM H2O2. Then, biotin-GSS-protein conjugates were precipitated
using streptavidin-agarose. Immunoblotting shows PFKFB3 levels before (input, bottom)
and after precipitation (upper) (60 μg of total protein per lane). (c) Detection of ROS-
induced S-glutathionylation of endogenous PFKFB3 in HeLa cells. With HeLa cells
transfected with the empty vector, an experiment similar to (b) was performed. (d) Detection
of ROS-induced S-glutathionylation of overexpressed (upper) and endogenous (lower)
PFKFB3. HeLa cells were treated with the indicated doses of BCNU to induce S-
glutathionylation and the experimental methods were the same as (b) and (c).
Immunoblotting shows PFKFB3 levels before (input, bottom) and after precipitation
(upper).
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Figure 4. A model for the carbohydrate flux upon PFKFB3 S-glutathionylation
(a) This diagram is provided to shows a hypothetical role played by S-glutathionylation of
PFKFB3 in a relationship between fructose-2,6-bisphosphate (Fru-2,6-BP), PFKFB3, and
the PPP. It has been hypothesized that increased S-glutathionylation of PFKFB3 leads to
decreases in the Fru-2,6-BP level and in the carbohydrate flux to glycolysis and, in turn, an
increase in the flux to the PPP and the level of GSH. Solid/bold lines represent direct, one-
step biochemical reactions, and indirect, multi-step reactions are represented by dotted lines.
Inhibition and activation of enzymatic steps are indicated by solid/plain lines. G-6-P,
glucose-6-phosphate; Ribul-5-P, ribulose-5-phosphate; Fru-6-P, fructose -6-phosphate;
Fru-1,6-BP, fructose-1,6-bisphosphate; Fru-2,6-BP, fructose-2,6-bisphosphate; PFKFB3-
SSG, S-glutathionylated PFKFB3; PFKFB3-SH, unglutathionylated PFKFB3. (b)
Enzymatic assay for rerouting of carbohydrate metabolic flux in response to PFKFB3 S-
glutathionylation. Changes in the formation of Fru-2,6-BP and NADPH from varied extents
of S-glutathionylation of PFKFB3 was measured. The extent of S-glutathionylation was
controlled with varied molar ratio of GSH to GSSG in a total concentration kept as 3 mM.
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Figure 5. PFKFB3 S-glutathionylation increases the carbohydrate flux to the PPP
(a) Intracellular Fru-2,6-P2 concentration, (b) the secreted lactate levels (c), cellular
concentration of Ribul-5P and Xyl-5P, (d) NADPH, and (e) GSH/GSSG ratio in HeLa cells
transiently expressing empty vector pcDNA3.1 (Con), expression plasmids for WT- or
C206A-PFKFB3 after treatment with 100 μM H2O2, 50 μM BCNU, or 1.5 mM GSHee to
induce PFKFB3 S-glutathionylation. Absolute values were normalized to the total protein
concentration and changes in metabolite levels are expressed as a percent of control (without
oxidant treatment). T-test (*P < 0.05, **P < 0.01, ***P< 0.001, $P<0.06 (marginally
significant); N.S., not significant) used for all the rest figures.
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Figure 6. Regulation of cellular ROS by PFKFB3 S-glutathionylation
(a) Intracellular ROS levels for empty vector (Con) and WT-PFKFB3 expression after H2O2
treatment. The results are expressed as the mean DCFru-fluorescence. Cell survival after 30
hrs treatment with H2O2 (b) or BCNU (c) using HeLa cells expressing empty vector
pcDNA3.1 (Con), expression plasmids for WT- or C206A-PFKFB3.
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a = b (Å) 102.50
c (Å) 260.61
Resolution range (Å) 47.7-2.2







No. amino acids 457
No. protein atoms 3676
No. hetero atoms 109
No. water molecules 160
r.m.s.d. from ideal
Bond lengths (Å) 0.024
Bond angles (deg.) 2.22
Dihedral angles (deg.) 20.5
Mean Bfactor
Protein atoms (Å2) 33.6
Hetero atoms (Å2) 47.5
Water atoms (Å2) 36.3
Rsym = Σh(Σj|Ih,j−<Ih>|/ΣIh,j), where h = set of Miller indices, j = set of observations of reflection h, and <Ih>=the mean intensity. Rcrys= Σh||
Fo,h|−|Fc,h||/Σh|Fo,h|. Rfree was calculated using 10% of the complete data set excluded from refinement. The numbers in parentheses represent
values from the highest resolution shell.
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